AnaptysBio (ANAB) Price Target Increased to $108.00 by Analysts at Royal Bank of Canada

AnaptysBio (NASDAQ:ANAB) had its price target increased by equities research analysts at Royal Bank of Canada to $108.00 in a report released on Monday, December 18th. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price target suggests a potential downside of 2.00% from the company’s previous close.

ANAB has been the topic of several other reports. SunTrust Banks began coverage on shares of AnaptysBio in a report on Wednesday, November 15th. They issued a “buy” rating and a $115.00 price objective on the stock. Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Robert W. Baird set a $69.00 target price on shares of AnaptysBio and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Credit Suisse Group upped their price target on AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $75.00 price target (up from $37.00) on shares of AnaptysBio in a report on Friday, October 13th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $88.00.

AnaptysBio (NASDAQ ANAB) traded down $1.09 during trading hours on Monday, hitting $110.20. 262,730 shares of the stock traded hands, compared to its average volume of 366,754. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77. The stock has a market cap of $2,530.00 and a price-to-earnings ratio of -72.98. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $114.47.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. equities research analysts forecast that AnaptysBio will post -1.72 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in ANAB. TIAA CREF Investment Management LLC purchased a new stake in shares of AnaptysBio during the first quarter worth approximately $227,000. Geode Capital Management LLC purchased a new stake in shares of AnaptysBio during the first quarter worth approximately $1,522,000. Bank of America Corp DE purchased a new position in AnaptysBio in the first quarter worth $123,000. Schwab Charles Investment Management Inc. raised its position in AnaptysBio by 94.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 19,402 shares of the biotechnology company’s stock worth $465,000 after acquiring an additional 9,414 shares in the last quarter. Finally, Alps Advisors Inc. purchased a new position in AnaptysBio in the second quarter worth $436,000. Institutional investors and hedge funds own 75.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://stocknewstimes.com/2018/01/11/anaptysbio-anab-pt-raised-to-108-00.html.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply